Roche (SIX: RO, ROG; OTCQX: RHHBY) and Oryzon Genomics SA today announced they have entered into a worldwide collaboration to research, develop and commercialize inhibitors of Lysine Specific Demethyl...
5-03-2014. Expertos internacionales analizan en el CIMA de la Universidad de Navarra los avances en investigación para mejorar los ensayos clínicos actuales
Un centenar de expertos interna...
Con motivo del Día Mundial contra el Cáncer, el Grupo Zeltia –que cumplirá 75 años el próximo 3 de agosto- ha consolidado su compromiso con la innovación en la lucha contra esta enfermedad,...
he First Specific LSD1 Inhibitor to Enter the Clinic.
Barcelona, Spain. January 16th, 2014. ORYZON, a biopharmaceutical company with a strong focus on epigenetics, hasannounced that has receiv...
Results presented include analyses of predictive biomarkers and novel mechanisms of resistance to targeted therapies, as well as the early results of whole exome and transcriptome sequencing in col...